Zobrazeno 1 - 10
of 416
pro vyhledávání: '"Mark Krailo"'
Autor:
Frances Chow, Michael Berens, Sharon Tamir, Yosef Landesman, Christopher Walker, Mark Krailo, Steven Gore, Jana Portnow
Publikováno v:
Journal of Clinical and Translational Science, Vol 7, Pp 126-126 (2023)
OBJECTIVES/GOALS: Selinexor is a novel XPO1 inhibitor that blocks nuclear export, thus impairing DNA repair and causing apoptosis. Our goal was to conduct preclinical and clinical studies to test our hypothesis that selinexor’s efficacy is boosted
Externí odkaz:
https://doaj.org/article/3b387fb5faa140c6aeea72dc7a79b29e
Autor:
Angela D. Trobaugh-Lotrario, Rudolf Maibach, Daniel C. Aronson, Arun Rangaswami, Beate Häberle, Allison F. O’Neill, Irene Schmid, Marc Ansari, Tomoro Hishiki, Sarangarajan Ranganathan, Rita Alaggio, Ronald R. de Krijger, Yukichi Tanaka, Soo-Jin Cho, Christian Vokuhl, Rebecca Maxwell, Mark Krailo, Eiso Hiyama, Piotr Czauderna, Milton Finegold, James H. Feusner, Marcio H. Malogolowkin, Rebecka L. Meyers, Dolores Lopez-Terrada
Publikováno v:
Cancers, Vol 15, Iss 2, p 467 (2023)
Small cell undifferentiated (SCU) histology and alpha-fetoprotein (AFP) levels below 100 ng/mL have been reported as poor prognostic factors in hepatoblastoma (HB); subsequent studies reported SMARCB1 mutations in some SCU HBs confirming the diagnosi
Externí odkaz:
https://doaj.org/article/68c08f92c5034801ac6dde50b1e74b5c
Autor:
Lori M. Minasian, A. Lindsay Frazier, Lillian Sung, Ann O’Mara, Joseph Kelaghan, Kay W. Chang, Mark Krailo, Brad H. Pollock, Gregory Reaman, David R. Freyer
Publikováno v:
Cancer Medicine, Vol 7, Iss 7, Pp 2951-2959 (2018)
Abstract Cisplatin is an essential chemotherapeutic agent in the treatment of many pediatric cancers. Unfortunately, cisplatin‐induced hearing loss (CIHL) is a common, clinically significant side effect with life‐long ramifications, particularly
Externí odkaz:
https://doaj.org/article/7b1f627d4f434d8ea2a66c7a68b0d1e1
Autor:
Neyssa Marina, Linda Granowetter, Holcombe E. Grier, Richard B. Womer, R. Lor Randall, Karen J. Marcus, Elizabeth McIlvaine, Mark Krailo
Publikováno v:
Sarcoma, Vol 2015 (2015)
Purpose. To associate baseline patient characteristics and relapse across consecutive COG studies. Methods. We analyzed risk factors for LESFT patients in three randomized COG trials. We evaluated age at enrollment, primary site, gender, tumor size,
Externí odkaz:
https://doaj.org/article/905083ea92bf4368885b66dcfc50857e
Publikováno v:
Journal of Cancer Survivorship. 17:4-16
Autor:
Pooja Hingorani, Mark Krailo, Allen Buxton, Paul Hutson, Paul M. Sondel, Mitchell Diccianni, Alice Yu, Carol D. Morris, Richard B. Womer, Brian Crompton, R Lor Randall, Lisa A. Teot, Steven G. DuBois, Katherine A. Janeway, Richard G. Gorlick, Michael S. Isakoff
Publikováno v:
European Journal of Cancer. 172:264-275
Novel effective therapies are urgently needed in recurrent osteosarcoma. GD2 is expressed in human osteosarcoma tumours and cell lines. This study evaluated the disease control rate (DCR) in patients with recurrent osteosarcoma treated with the anti-
Autor:
Nirmish Singla, Justin Wong, Shyamli Singla, Mark Krailo, Li Huang, Furqan Shaikh, Deborah Billmire, Frederick Rescorla, Jonathon Ross, Bryan Dicken, James F. Amatruda, A. Lindsay Frazier, Aditya Bagrodia
Publikováno v:
Journal of Pediatric Urology. 18:505-511
Patients with clinical stage I (CS I: cN0M0) testicular germ cell tumors (TGCT) exhibit favorable oncologic outcomes. While prognostic features can help inform treatment in adults with CS I TGCT, we lack reliable means to predict relapse among pediat
Autor:
Katherine E. Warren, Gilbert Vezina, Mark Krailo, Linda Springer, Allen Buxton, Cody J. Peer, William D. Figg, Chris William-Hughes, Sandy Kessel, Maryam Fouladi, Amar Gajjar, Daniel Bowers
Publikováno v:
Journal of Clinical Oncology.
PURPOSE Children with low-grade glioma often require long-term therapy and suffer from treatment morbidity. Although targeted agents are promising, tumor targets often encompass normal developmental pathways and long-term effects of inhibition are un
Autor:
Brenda J. Weigel, Susan M. Blaney, Stacey L. Berg, Stephan D. Voss, Mark Krailo, Donald A. Barkauskas, David Hall, Malcolm A. Smith, Peter J. Houghton, Richard B. Lock, Hernan Carol, Stephanie L. Safgren, Joel M. Reid, David T. Teachey, Elizabeth Fox, Yael P. Mossé
Purpose:Aurora A kinase (AAK) plays an integral role in mitotic entry, DNA damage checkpoint recovery, and centrosome and spindle maturation. Alisertib (MLN8237) is a potent and selective AAK inhibitor. In pediatric preclinical models, antitumor acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f1dc91e84c94f88674693e3c59af6cb
https://doi.org/10.1158/1078-0432.c.6527514.v1
https://doi.org/10.1158/1078-0432.c.6527514.v1
Autor:
Tsz-Kwong Man, John M. Hicks, Donald A. Barkauskas, Mark Krailo, Ching C. Lau, Aaron J. Kelly, Manjula Nakka, Yiting Li
This file contains Supplementary Table S1. The clinical information of the cohort collected from Texas Children's Hospital and the cohort collected from the Children's Oncology Group Supplementary Table S2. Autoantibody candidates showed higher inten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bd04f833beb58dc3c9c712ad18e19b1
https://doi.org/10.1158/0008-5472.22411964.v1
https://doi.org/10.1158/0008-5472.22411964.v1